- Home
- YETI vs CNTA Comparison
YETI vs CNTA Comparison
Compare YETI & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YETI
- CNTA
- Stock Information
- Founded
- YETI 2006
- CNTA 2020
- Country
- YETI United States
- CNTA United Kingdom
- Employees
- YETI N/A
- CNTA N/A
- Industry
- YETI Recreational Games/Products/Toys
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- YETI Consumer Discretionary
- CNTA Health Care
- Exchange
- YETI Nasdaq
- CNTA Nasdaq
- Market Cap
- YETI 2.5B
- CNTA 2.3B
- IPO Year
- YETI 2018
- CNTA 2021
- Fundamental
- Price
- YETI $35.63
- CNTA $20.85
- Analyst Decision
- YETI Buy
- CNTA Strong Buy
- Analyst Count
- YETI 13
- CNTA 11
- Target Price
- YETI $38.67
- CNTA $30.60
- AVG Volume (30 Days)
- YETI 1.6M
- CNTA 1.2M
- Earning Date
- YETI 11-06-2025
- CNTA 08-12-2025
- Dividend Yield
- YETI N/A
- CNTA N/A
- EPS Growth
- YETI N/A
- CNTA N/A
- EPS
- YETI 2.10
- CNTA N/A
- Revenue
- YETI $1,822,000,000.00
- CNTA $15,000,000.00
- Revenue This Year
- YETI $3.23
- CNTA N/A
- Revenue Next Year
- YETI $4.87
- CNTA N/A
- P/E Ratio
- YETI $16.99
- CNTA N/A
- Revenue Growth
- YETI 3.63
- CNTA 118.88
- 52 Week Low
- YETI $26.61
- CNTA $9.60
- 52 Week High
- YETI $45.25
- CNTA $20.66
- Technical
- Relative Strength Index (RSI)
- YETI 52.85
- CNTA 73.39
- Support Level
- YETI $34.35
- CNTA $15.01
- Resistance Level
- YETI $36.98
- CNTA $17.68
- Average True Range (ATR)
- YETI 1.01
- CNTA 1.08
- MACD
- YETI 0.07
- CNTA 0.16
- Stochastic Oscillator
- YETI 63.01
- CNTA 99.66
About YETI YETI Holdings Inc.
YETI Holdings Inc is a designer, marketer, and distributor of premium products for the outdoor and recreation market sold under the YETI brand. The company offers products including coolers and equipment, drinkware, and other accessories. Its trademark products include YETI Tundra, Hopper, YETI TANK, Rambler, Colster, Rambler among others. The company distributes products through wholesale channels and through direct-to-consumer, or DTC, channels.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.